News | Oct 16, 2006
License to Osmetech plc.
Osmetech licenses pharmacogenetic marker for P450-CYP2D6 from
Bernried, Germany - October 16, 2006 - EPIDAUROS Biotechnologie AG, a leading provider of pharmacogenetic solutions located in Bernried near Munich, and Osmetech plc., an international healthcare diagnostics group, jointly announce today that Osmetech has signed an agreement for a non-exclusive commercial license to EPIDAUROS´ patent application on a specific biomarker related to the Cytochrome P450 2D6. Financial details are not disclosed.
The agreement covers the genetic variant 2988G>A in the CYP2D6 gene. This variant could be used in combinatorial analysis with further genetic variants of CYP2D6 as a predictive marker for impaired enzymatic function putting patients at higher risk for non-responsiveness or adverse drug reactions. CYP2D6 plays a role in the metabolism of 25% of the most commonly prescribed drugs to date. Therefore, the sound analysis of CYP2D6 is important in the course of clinical drug development to make drug therapy safer and more efficacious.
Contact EPIDAUROS
Dr. Michael Lutz
Chief Executive Officer
Dr. Stephan Reschauer
Director
Patents & Licensing
Phone: +49 (0)8158 9985 0
Fax: +49 (0)8158 9985 48
Email: contact@epidauros.com
File(s) | ||
 | Size: 108 K | |